EUVIMEDEUVIMED entdecken
Crossref

Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders

Emre Özoran, İbrahim Halil Özata, Derya Salim Uymaz, Nail Omarov, Emre Bozkurt, Tutku Tüfekçi, Salih Nafiz Karahan, Bülent Gürbüz, Fatih Selçukbiricik, Yasemin Bölükbaşı, Orhun Çığ Taşkın, Bengi Gürses und 3 weitere

International Journal of Colorectal Disease · 2023

DOI: 10.1007/s00384-023-04526-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2023. Verfasst von Emre Özoran und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey. eozoran@ku.edu.tr. Hauptthemen laut MEDLINE: Abdominal Cavity, Neoplasms, Second Primary, Rectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to compare local regrowth rates after total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (SNCRT) in locally advanced rectal cancer (LARC) patients that were strictly selected and assessed with a multimodal approach. Secondary outcomes were 4-year disease-free (DFS) and overall survival (OS) rates. METHODS: Locally advanced rectal cancer patients without distant metastases treated at Koç Healthcare Group between January 2014 and January 2021 were included. Patients were assessed for complete response with a combination of digital rectal exam, endoscopy, and magnetic resonance imaging with a dedicated rectum protocol. The systemic evaluation was performed with an upper abdomen MRI using intravenous hepatobiliary contrast agent and a thorax CT. RESULTS: Of the 270 patients with LARC, 182 fulfilled the inclusion criteria. Ninety-seven (53.3%) underwent TNT, while 85 (46.7%) underwent SNCRT. A cumulative combination of pathological and sustained clinical complete response was significantly higher in the TNT group than in the SNCRT (45.4% vs. 20.0%, p < 0.0001). After a median follow-up of 48 months, seven patients in the W&W group had regrowth [TNT: 4 (10.8%) vs. SNCRT: 3 (23.1%), p = 0.357]. Based on pathological examination, complete/near complete mesorectum rates (p = 1.000) and circumferential resection margin positivity rates (p = 1.000) were similar between the groups. The 4-year DFS and OS rates were comparable. The patients with clinical or pathological complete response had significantly longer overall survival (p = 0.017) regardless of the type of neoadjuvant treatment. CONCLUSIONS: Multimodal assessment after TNT effectively detects complete responders, resulting in low local recurrence and increased cumulative complete response rates. However, these outcomes did not translate into a survival advantage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abdominal CavityNeoplasms, Second PrimaryRectal NeoplasmsHumansRectumNeoadjuvant TherapyPelvis

Stichwörter der Autor:innen

Consolidation chemotherapyInduction chemotherapyRectal cancerStandard neoadjuvant chemoradiotherapyTotal neoadjuvant therapy

Autor:innen und Institutionen

  • Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey. eozoran@ku.edu.tr.
  • Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey.
  • Department of General Surgery, VKV American Hospital, Istanbul, Turkey.
  • Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Pathology, Koç University School of Medicine, Istanbul, Turkey.

Zitieren

APA

Özoran, E., Özata, İ. H., Uymaz, D. S., Omarov, N., Bozkurt, E., Tüfekçi, T., Karahan, S. N., Gürbüz, B., Selçukbiricik, F., Bölükbaşı, Y., Taşkın, O. Ç., Gürses, B., Rencüzoğulları, A., Buğra, D., & Balık, E. (2023). Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-023-04526-2

Vancouver

Özoran E, Özata İH, Uymaz DS, Omarov N, Bozkurt E, Tüfekçi T, et al. Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders. International Journal of Colorectal Disease. 2023. doi:10.1007/s00384-023-04526-2

BibTeX
@article{zoran2023,
  author = {Özoran, Emre and Özata, İbrahim Halil and Uymaz, Derya Salim and Omarov, Nail and Bozkurt, Emre and Tüfekçi, Tutku and Karahan, Salih Nafiz and Gürbüz, Bülent and Selçukbiricik, Fatih and Bölükbaşı, Yasemin and Taşkın, Orhun Çığ and Gürses, Bengi and Rencüzoğulları, Ahmet and Buğra, Dursun and Balık, Emre},
  title = {Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders},
  journal = {International Journal of Colorectal Disease},
  year = {2023},
  doi = {10.1007/s00384-023-04526-2}
}
Kostenlos starten →